Highly Sensitive Single Domain Antibody–Quantum Dot Conjugates for Detection of HER2 Biomarker in Lung and Breast Cancer Cells
journal contributionposted on 24.06.2014 by Tatsiana Y. Rakovich, Omar K. Mahfoud, Bashir M. Mohamed, Adriele Prina-Mello, Kieran Crosbie-Staunton, Tina Van Den Broeck, Line De Kimpe, Alyona Sukhanova, Daniel Baty, Aliaksandra Rakovich, Stefan A. Maier, Frauke Alves, Frans Nauwelaers, Igor Nabiev, Patrick Chames, Yuri Volkov
Any type of content formally published in an academic journal, usually following a peer-review process.
Despite the widespread availability of immunohistochemical and other methodologies for screening and early detection of lung and breast cancer biomarkers, diagnosis of the early stage of cancers can be difficult and prone to error. The identification and validation of early biomarkers specific to lung and breast cancers, which would permit the development of more sensitive methods for detection of early disease onset, is urgently needed. In this paper, ultra-small and bright nanoprobes based on quantum dots (QDs) conjugated to single domain anti-HER2 (human epidermal growth factor receptor 2) antibodies (sdAbs) were applied for immunolabeling of breast and lung cancer cell lines, and their performance was compared to that of anti-HER2 monoclonal antibodies conjugated to conventional organic dyes Alexa Fluor 488 and Alexa Fluor 568. The sdAbs–QD conjugates achieved superior staining in a panel of lung cancer cell lines with differential HER2 expression. This shows their outstanding potential for the development of more sensitive assays for early detection of cancer biomarkers.